The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma Background: To determine the frequency and predictive impact of ROS1 rearrangements on treatment outcomes in never-smoking patients with lung adenocarcinoma.
to EGFR-tyrosine kinase inhibitors in patients harboring ROS1 rearrangement was shorter than those without ROS1/ALK rearrangement (2.5 versus 7.8 months; P = 0.01).
Conclusions:
The frequency of ROS1 rearrangements in clinically selected patients is higher than that reported for unselected patients, suggesting that ROS1 rearrangement is a druggable target in East-Asian never smokers with lung adenocarcinoma. Given the different treatment outcomes to conventional therapies and availability of ROS1 inhibitors, identification of ROS1 rearrangement can lead to successful treatment in ROS1-rearranged lung adenocarcinomas. Key words: lung adenocarcinoma, never smoker, outcome, ROS1 introduction Lung cancer in never smokers (LCINS) is regarded as a distinct disease entity with a distinct molecular subclassification [1] . Notably, actionable mutations in epidermal growth factor receptor (EGFR), KRAS, and anaplastic lymphoma kinase (ALK)-rearrangement are three major recurrent oncogenic alterations in LCINS [1] [2] [3] . Other genetic aberrations in LCINS include HER2 mutations and KIB5B-RET fusion, although these mutations are known to occur with low frequencies [4] .
Recently, ROS1 rearrangement has emerged as a new molecular subtype in non-small-cell lung cancer (NSCLC), and now comprises a distinct molecular classification of NSCLC. ROS1 rearrangement in NSCLC was discovered in 2007 by Rikova, who identified two ROS1 fusion products (SLC34A2-ROS1 and CD74-ROS1) in a cell line and a tumor with high ROS1 phospho-peptides [5] . ROS1 rearrangements result in the formation of fusion proteins having constitutive tyrosine-kinase activity through the dimerization of ROS1 fusion partners which subsequently stimulates downstream signaling, resulting in enhanced cell growth, proliferation, and decreased apoptosis.
In an unselected NSCLC population, the frequency of ROS1 rearrangement ranged from 0.9% to 1.7% [3, 6, 7] . Recently, Bergethon et al. [3] reported a strong association between ROS1 rearrangements and never smoking. However, because most studies investigated predominantly smokers, the frequency of ROS1 rearrangements in East-Asian never smokers remains unknown. Furthermore, whether patients with ROS1-rearranged NSCLC share similar outcomes to other genetically defined subsets, particularly in the metastatic setting, also is unknown.
Preclinical and clinical data have demonstrated that ROS1-positive tumors are sensitive to crizotinib [3] . This indicates that ROS1-positive NSCLC represents a novel patient subset that may derive clinical benefit from ROS1 inhibition [8] . Preliminary data from a phase I trial of crizotinib (NCT00585195) in the ROS1-positive NSCLC expansion-cohort demonstrated an overall response rate (ORR) of 57%. However, the sensitivity of ROS1-positive NSCLC to cytotoxic chemotherapy or EGFR-tyrosine kinase inhibitors (TKIs) in patients with NSCLC with ROS1 fusions has not been evaluated.
Herein, we determined the frequency of ROS1 rearrangement with the identification of fusion partners in the largest-ever cohort of East-Asian never smokers with NSCLC. We also examined the clinicopathological characteristics and treatment outcomes of patients with lung adenocarcinomas with ROS1 rearrangement.
materials and methods

study population and data collection
This study was conducted in a cohort of histologically confirmed never smokers with lung adenocarcinoma at Severance Hospital, Seoul, Korea, between January 2005 and February 2012. The criteria used for patient selection included: (i) availability of tumor tissue, (ii) smoking-history, (iii) genetic data (EGFR and KRAS mutation and ALK rearrangement), and (iv) survival data. Tumor histology was classified using the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of Lung Adenocarcinoma. Never smokers were defined as those with a lifetime smoking dose of <100 cigarettes. A total of 208 consecutive never smokers with histologically confirmed lung adenocarcinoma were enrolled.
A predesigned data collection format was used to review the patients' medical records for evaluation of clinicopathological characteristics and survival outcomes. For patients with metastatic disease, we examined treatment regimens, ORR, and survival outcomes. Clinical responses were classified using the Response Evaluation Criteria in Solid Tumor (RECIST version 1.1). Progression-free survival (PFS) was measured from the first day of treatment to tumor progression or death, while overall survival (OS) was measured from the date of diagnosis of metastatic disease until the date of death. Patients were censored on 26 October 2012, if alive and progression free. Patients without a known date of death were censored at the time of last follow-up. This study was approved by the Institutional Review Board of Severance Hospital. All patients signed a written informed consent for genetic analysis.
ROS1 rearrangements
To identify ROS1 rearrangements, fluorescent in situ hybridization (FISH) assays were carried out on formalin-fixed and paraffin-embedded (FFPE) tumors by using a break-apart probe to ROS1 (Break-Apart Rearrangement Probe; Abbott Molecular®) according to manufacturer's instructions. FISH-analyses were interpreted by two experienced evaluators (HSS and JKP) who were blinded to the clinical and genetic data. At least 100 nuclei per case were evaluated. FISH positivity for ROS1 rearrangement was defined as >15% of tumor cells with a split signal. FISH-positive tumors were confirmed by immunohistochemistry (IHC) using antibody against ROS1. FFPE tissues were sectioned at a thickness of 4 μm and stained using Ventana automated immunostainner BenchMark XT. The slides were dried at 60°C for 1 h and deparaffinized using EZ Prep at 75°C for 4 min. Cell conditioning was carried out using CC1 solution at 100°C for 64 min. ROS1 antibody (rabbit monoclonal, clone D4D6, Cell Signaling Technology) was diluted to 1:50, treated, and incubated at 37°C for 32 min. Signals were detected using OptiView DAB IHC Detection Kit (Ventana Medical Systems). Counterstaining was carried out with Hematoxylin I for 4 min at room temperature.
To identify the known fusion partners of ROS1, reverse transcriptasepolymerase chain reaction (RT-PCR) was carried out using the SuperScript Annals of Oncology original articles III First-Strand Synthesis System (Invitrogen) with a previously published ROS1 primer located in exon 32, exon 34, exon 35, and exon 36 [9] . PCR products positive for the ROS1 fusions were excised from the agarose gel, purified (Wizard SV Gel and PCR Clean-Up Kit; Promega), and then sequenced.
thymidylate synthase IHC and scoring
Thymidylate synthase (TS) antibody (rabbit polyclonal, clone H-265, Santa Cruz Biotechnology) was diluted to 1:50, treated, and incubated at 37°C for 32 min. For TS, a semiquantitative scoring was used, and the results were represented as intensity multiplied by proportion.
ALK rearrangements, EGFR, and KRAS mutation analysis
To identify ALK rearrangements, FISH studies were carried out on FFPE tumors by using a break-apart probe to ALK (Vysis LSI ALK Dual Color, Break-Apart Rearrangement Probe; Abbott Molecular) [2] . Nucleotide sequencing of the kinase domain of EGFR (exons 18 to 21) and KRAS exon 2 (codons 12/13) was carried out using nested PCR-amplification of the individual exons [2] . Details of these methods have been described previously [2] .
cell culture and cell viability assay
The human NSCLC cell lines, A549, H460, H1299, HCC827, and H2228, were purchased from the American Type Culture Collection and PC-9 and H3122 were kind gifts from Drs K. Hayata (Tokyo Medical College) and John D. Minna (University of Texas Southwestern). After cells were exposed to drugs for 72 h, 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) solution was added to the well. The optical density of the MTT formazan product was read at 565 nm on a microplate reader.
statistical analysis
Significant differences in variables according to each genotype were tested using the χ 2 test, Fisher's exact test, or t-test, as appropriate. The
Kaplan-Meier method was used to estimate PFS and OS, and the differences according to genotype were compared using the log-rank test. Adjusted hazard ratios (AHRs) for the risk of progression or death in response to treatment according to genotype were calculated using a Cox-regression model that included age, gender, and genetic alteration as independent variables. All P-values were based on a two-tailed hypothesis.
results clinicopathologic characteristics of patients with ROS1 rearrangement
We screened ROS1 rearrangements in 208 never smokers with lung adenocarcinoma. ROS1-positive lung adenocarcinoma was detected in 7 of 208 samples (3.4%). There was no significant difference in baseline characteristics between ROS1-positive and -negative cases. The median age of ROS1 positive was numerically younger than that of ROS1 negative without statistical significance, probably due to the fact that the majorities in our study were elderly women (Table 1) . Although ROS1 rearrangement was mutually exclusive from ALK rearrangement and KRAS mutation, one of seven ROS1-positive Figure S1 , available at Annals of Oncology online).
identification of ROS1 fusion partners by RT-PCR
We found CD74-ROS1 fusions in two patients by RT-PCR and sequencing (supplementary Figure S2 , available at Annals of Oncology online). No fusion partner was identified in the remaining five tumors. The latest update of ROS1 fusion partners including our results is illustrated in supplementary Figure S3 , available at Annals of Oncology online.
treatment outcomes of ROS1-rearranged lung adenocarcinoma Table 2 summarized the treatment outcomes in 162 metastatic lung adenocarcinoma patients who received palliative chemotherapy. Single agent pemetrexed either in the second-or third-line setting was administered in a total of 82 patients (50.6%). The ORR to pemetrexed in ROS1-positive patients was higher than that in WT/WT (60.0% versus 8.5%; P = 0.01).
EGFR-TKIs were administered in 120 patients as a second or third line. None had received ALK inhibitors previously. None of the patients with ROS1 rearrangement (n = 3) had a clinical response to EGFR-TKIs. Similarly, there was no responder to EGFR-TKIs among patients with ALK rearrangement. The ORR to EGFR-TKIs in patients with ROS1 rearrangement was numerically lower than that in WT/WT, although not statistically significant (0% versus 25.7%). These results might be due to a small sample size. With a median follow-up duration of 29.6 months, 82 (39.4%) of 208 patients were still alive at the time of analysis. ROS1 rearrangement conferred a significantly longer median PFS with pemetrexed than WT/WT (not reached versus 3.3 months for WT/WT; P = 0.008; Figure 1B) . However, patients with ROS1 rearrangement showed significantly shorter median PFS to EGFR-TKIs than WT/WT (2.5 versus 7.8 months in WT/WT; P = 0.01; Figure 1C ). Additionally, we compared the treatment outcome of EGFR-TKI in ROS1-positive patients with that of triple-negative for EGFR/ALK/ROS1. There was no difference in treatment outcome of EGFR-TKI in terms of ORR and PFS.
In a Cox-regression model adjusted for age, gender, EGFR mutation, and ALK rearrangement, the AHR for the risk of disease progression to pemetrexed was 0.09 (P = 0.02) for patients with ROS1 rearrangement. This suggests that ROS1 The patient with concurrent ROS1 rearrangement and EGFR mutation was not included in the response analysis in EGFR-TKI. WT, wild type; CT, chemotherapy; EGFR, epidermal growth factor receptor; NS, not significant; TKIs, tyrosine kinase inhibitors; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate (CR + PR + SD).
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rearrangement is a strong predictive factor for a longer median PFS to pemetrexed. The AHR for the risk of progression to the EGFR-TKIs was 2.40 (P = 0.14) for ROS1 rearrangement, 0.56 (P = 0.007) for EGFR mutation, and 2.70 (P = 0.02) for ALK rearrangement (supplementary Table S2 , available at Annals of Oncology online). These results indicate that EGFR mutations are a strong positive predictive factor for a longer median PFS after EGFR-TKI, whereas ALK rearrangements have a negative predictive impact. Furthermore, ROS1 rearrangement may be a negative predictor for a longer PFS to EGFR-TKI, although statistical significance was not reached likely due to sample size limitation.
pemetrexed inhibits ROS1 activity and cell growth in vitro
We carried out a cell viability assay in various NSCLC cell lines using pemetrexed, gefitinib, crizotinib, and TAE684. Pemetrexed is highly sensitive, but gefitinib is resistant to ROS1-rearranged HCC78 and ALK-rearranged H3122. As the TS expression has been reported to be associated with the sensitivity to pemetrexed [10] , we examined TS level in various cell lines. TS expression was rarely detected in pemetrexedsensitive HCC78, H3122, PC9, and HCC827, while pemetrexedresistant H358 and H1299 showed high TS expression ( Figure 2 ). As shown in supplementary Figure S4 , available at Annals of Oncology online, patients with ROS1 or ALK rearrangement tend to show lower TS scoring than those with WT/WT.
discussion
We reported the frequency and treatment outcomes of ROS1-rearranged NSCLC from East-Asian never smokers. The enrichment of never smokers resulted in a higher frequency (3.4%) of ROS1 rearrangement compared with that in unselected populations (0.9%∼1.7%), further supporting that ROS1 rearrangements, together with EGFR mutations and ALK rearrangements, are the genetic alterations that are specific for LCINS [2, 3] . ROS1 rearrangements were mutually exclusive with three major recurrent oncogenic mutations in LCINS, such as EGFR or KRAS mutation or ALK rearrangement, comprising a unique and nonoverlapping molecular subset of LCINS. The treatment outcome of ROS1-rearranged NSCLC was distinct from that of WT/WT tumors, but similar to that of ALKrearranged NSCLC, which may suggest the biological similarity of ROS1-and ALK-rearranged NSCLC. To our knowledge, this is the first and the most comprehensive study reporting the frequency, clinicopathologic features, and treatment response at the same time in ROS1-rearranged lung adenocarcinomas from East-Asian never smokers. Several studies have examined the frequency of ROS1 rearrangement in NSCLC. Bergethon et al. [3] reported that ROS1 rearrangements were enriched in Asians and never smokers. However, in the other studies that primarily involved Asian patients and/or never smokers, the frequency of ROS1 rearrangement has been reported to range from 0.9% to 1.6%, which was similar to that reported in unselected population [6, 7, 11] . Potential explanations for the lower frequency of ROS1 rearrangement in these studies may exist. In a report by Li et al., the authors examined ROS1 rearrangement by RT-PCR which limited the detection of fusion partners to CD74 and SLC34A2 only. Rimkunas et al. [7] screened ROS1 rearrangements using IHC assay from Chinese patients with unknown smokingstatus. A study by Takeuchi et al. [6] investigated predominantly smokers. Recently, Cai et al. [12] reported that the ROS1 rearrangements were found in ∼2.0% of Chinese patients and had worse survival outcome compared with ROS1 negative. Unfortunately, most of the above studies did not concurrently analyze EGFR and KRAS mutations and ALK rearrangements, the three most frequently identified and clinically relevant genetic alterations in LCINS.
With the screening for ROS1 rearrangements by using FISH and the enrichment of never smokers, we original articles Annals of Oncology demonstrated that the frequency of ROS1 rearrangements was 3.4%, suggesting that ROS1 rearrangement is a druggable target in East-Asian never smokers with lung adenocarcinoma. Notably, the frequency of ROS1 rearrangements was 5.7% among EGFR/KRAS/ALK-negative patients. Taken together, our data suggest that ROS1 rearrangements were associated with never-smoking status, especially in patients who are negative for three major oncogenic mutations most frequently identified in LCINS [2] .
In our study, ROS1 rearrangement was associated with a different response and survival outcome after EGFR-TKIs and/or pemetrexed treatment. Patients with ALK and ROS1 rearrangement had poorer outcomes after EGFR-TKIs. Intriguingly, we noted that patients with ROS1 rearrangement had a significantly better ORR and median PFS on pemetrexed than those without ROS1 rearrangement. Similarly, previous studies have shown that ALK-positive patients had significantly longer PFS on pemetrexed compared with ALK negative [13] . It was suggested that ALK-positive tumors had low level of TS, leading to high susceptibility to pemetrexed. Our study demonstrated that patients with ALK rearrangement tend to show favorable PFS to pemetrexed compared with WT/WT even with no statistical significance. The reason for discrepancies with previous data could be explained by following limitations of our study; retrospective data, small number of ALK positive, and treatment of pemetrexed as third line and more over. We also discovered low TS level and the highest sensitivity to pemetrexed in ROS1-positive HCC78, compared with other cell lines. The similar clinical characteristics might be related with the structural and functional homology between two genotypes. However, the underlying mechanism for the favorable response to pemetrexed is still unclear. Since this was a retrospective study and that the number of ROS1 positive was small, we think that the sensitivity to pemetrexed of ROS1-positive patients should be cautiously interpreted.
To date, eight ROS1 fusion genes including CD74-ROS1, SLC34A2-ROS1, SDC4-ROS1, EZR-ROS1 , FIG-ROS1 , TPM3-ROS1, LRIG3-ROS1, and KDELR2-ROS1 have been identified. Among them, CD74-ROS1 is the most common fusion partner in NSCLC [3, 5-7, 9, 11, 12, 14-16] . In our study, CD74 was found as a fusion partner in two patients. No fusion partner was identified in the other five cases, possibly due to insufficient tissue sample or poor quality of extracted RNA in FFPE. Regarding the ALK result in our study, the 7.2% prevalence and mutual exclusiveness with EGFR and/or KRAS mutation is very similar with recent data [17, 18] .
In conclusion, ∼3.4% of lung adenocarcinoma from EastAsian never smokers harbors ROS1 rearrangement. Because of the different treatment outcomes and the existence of ROS1 inhibitors in this molecular subset, the identification of ROS1 rearrangement before the initiation of treatment should be a routine practice in personalized therapy.
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